The following two presentations are from last week's ABN meeting in Birmingham on the topic of the need for combination therapies. It is clear that based on the current efficacy profile of DMTs if we are going to make a difference to people with MS we are going to need to build a sandwich of treatments targeting different pathogenic, including premature ageing.
I gave these presentations as back-to-back talks on the silent symposium platform. A silent symposium is when you speak softly into a microphone and your audience listens to you wearing headsets. The idea is to allow the symposium to occur in the same venue as the posters and exhibitions and make too much noise; not too dissimilar to a silent disco.